La protección comunitaria: el enfoque del CICR

El CICR intenta garantizar que sus actividades en favor de los desplazados internos y aquellos en riesgo de desplazamiento sean un apoyo y no menoscaben los mecanismos ni las estrategias de resolución de problemas de las comunidades y los individuos

Low to middle Pleistocene paleoclimatic record from the Kraków-Częstochowa Upland (Poland) based on isotopic and calcite fabrics analyses

The quality of paleoenvironmental reconstruction based on speleothem records depends on the accuracy of the used proxies and the chronology of the studied record. As far as the dating method is concerned, in most cases, the best solution is the use of the U-series method to obtain a precise chronology. However, for older periods (i.e., over 0.5 Ma), dating has become a serious challenge. Theoretically, older materials could be dated with the U-Pb dating method. However, that method re-quires a relatively high uranium content (minimum of several ppm), whereas typical speleothems from Poland (and all of Central Europe) have uranium concentrations below 0.1 ppm. Because the materials in Polish caves are problematic, we applied oxygen isotope stratigraphy (OIS) as a tool for speleothem dating. By using OIS as an alternative tool to create a chronology of our flowstone, it was found that the studied flowstone crystallized from 975 to 470 ka with three major discontinuities, so obtained isotopic record can be correlated with oxygen isotopic stages from MIS 24 to MIS 12. The observed isotopic variability was also consistent and confirmed with the petrographic observations of the flowstone

Xanthine Oxidoreductase Reference Values in Platelet-Poor Plasma and Platelets in Healthy Volunteers

Introduction. Xanthine oxidoreductase (XOR) is an enzyme belonging to the class of hydroxylases. XOR is stated, inter alia, in the kidneys, liver, and small intestine as well as in leukocytes and platelets and endothelial cells of capillaries. Its main role is to participate in the conversion of hypoxanthine to xanthine and the uric acid. It occurs in two isoforms: dehydrogenase (XD) and oxidase (XO), which is considered one of the sources of reactive oxygen species. Aim of the Study. Determination of reference values of xanthine oxidoreductase activity in PPP and platelets. Materials and Methods. Study group consisted of 70 healthy volunteers. The isoform activities of xanthine oxidoreductase were determined by kinetic spectrophotometry. Results. A statistically significant difference between the activity of the XOR in PPP and platelets (P<0.001). The highest activity of XO was found in both PPP and blood platelets. Significant differences between the activity of the various isoforms in PPP (P=0.0032) and platelets (P<0.001) were also found. Conclusions. The healthy volunteers showed the highest activity XO (prooxidant) and the lowest XD (antioxidant), which indicates a slight oxidative stress and confirmed physiological effects of XOR

Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)

Background: Graves' orbitopathy (GO) is subject to epidemiological and care-related changes. Aim of the survey was to identify trends in presentation of GO to the European Group On Graves' Orbitopathy (EUGOGO) tertiary referral centres and initial management over time. Methods: Prospective observational multicentre study. All new referrals with diagnosis of GO within September-December 2019 were included. Clinical and demographic characteristics, referral timelines and initial therapeutic decisions were recorded. Data were compared with a similar EUGOGO survey performed in 2012. Results: Besides age (mean age: 50.5±13 years vs 47.7±14 years; p 0.007), demographic characteristics of 432 patients studied in 2019 were similar to those in 2012. In 2019, there was a decrease of severe cases (9.8% vs 14.9; p&lt;0.001), but no significant change in proportion of active cases (41.3% vs 36.6%; p 0.217). After first diagnosis of GO, median referral time to an EUGOGO tertiary centre was shorter (2 (0-350) vs 6 (0-552) months; p&lt;0.001) in 2019. At the time of first visit, more patients were already on antithyroid medications (80.2% vs 45.0%; p&lt;0.001) or selenium (22.3% vs 3.0%; p&lt;0.001). In 2019, the initial management plans for GO were similar to 2012, except for lid surgery (2.4% vs 13.9%; p&lt;0.001) and prescription of selenium (28.5% vs 21.0%; p 0.027). Conclusion: GO patients are referred to tertiary EUGOGO centres in a less severe stage of the disease than before. We speculate that this might be linked to a broader awareness of the disease and faster and adequate delivered treatment